Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report

Tani,Tetsuo; Naoki,Katsuhiko; Asakura,Takanori; Hirano,Toshiyuki; Suzuki,Shoji; Masuzawa,Keita; Hasegawa,Hanako; Kuroda,Aoi; Yasuda,Hiroyuki; Ishii,Makoto; Soejima,Kenzo; Betsuyaku,Tomoko

doi:10.3892/mco.2016.981

October-2016 Volume 5 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2016 Volume 5 Issue 4

Full Size Image

Case Report

Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report

Authors:
- Tetsuo Tani
- Katsuhiko Naoki
- Takanori Asakura
- Toshiyuki Hirano
- Shoji Suzuki
- Keita Masuzawa
- Hanako Hasegawa
- Aoi Kuroda
- Hiroyuki Yasuda
- Makoto Ishii
- Kenzo Soejima
- Tomoko Betsuyaku
View Affiliations / Copyright

Affiliations: Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku, Tokyo 160‑8582, Japan, Cancer Center, Keio University School of Medicine, Shinjuku, Tokyo 160‑8582, Japan
Pages: 488-490
|
Published online on: August 4, 2016

https://doi.org/10.3892/mco.2016.981
Expand metrics +

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI)‑induced interstitial lung disease (ILD) may be a life‑threatening condition that may develop during treatment of lung cancer patients harboring EGFR mutations. We herein present the case of a 41‑year‑old female patient diagnosed with lung adenocarcinoma with an EGFR mutation (exon 19 deletion). The patient was treated with gefitinib followed by erlotinib and developed ILD induced by both EGFR‑TKIs; furthermore, the patient acquired resistance to EGFR‑TKI treatment. A repeat biopsy revealed a T790M mutation, which is associated with resistance to first-generation EGFR‑TKIs, along with an exon 19 deletion identified by cytology of the pleural fluid. Treatment with afatinib and prednisolone resulted in tumor shrinkage, without worsening of the ILD. The present case demonstrated that combination treatment with afatinib and a glucocorticoid may be effective for the treatment of lung cancer patients who develop EGFR‑TKI‑induced ILD.

View Figures

View References

1	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
2	Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, et al: In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 6:38789–38803. 2015.PubMed/NCBI
3	Naoki K, Soejima K, Okamoto H, Hamamoto J, Hida N, Nakachi I, Yasuda H, Nakayama S, Yoda S, Satomi R, et al: The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. Int J Clin Oncol. 16:335–344. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hata A, Katakami N, Yoshioka H, Kaji R, Masago K, Fujita S, Imai Y, Nishiyama A, Ishida T and Nishimura Y: Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol. 10:1553–1559. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, et al: Interstitial lung disease in Japanese patients with lung cancer. A cohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
6	Shi L, Tang J, Tong L and Liu Z: Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer. 83:231–239. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y and Fukuoka M: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 24:2549–2556. 2006. View Article : Google Scholar : PubMed/NCBI
8	Endo M, Johkoh T, Kimura K and Yamamoto N: Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer. 52:135–140. 2006. View Article : Google Scholar : PubMed/NCBI
9	Arakawa N, Tsujita A, Saito N, Ishikawa S and Ohno S: Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases. Respirol Case Rep. 1:17–19. 2013.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles